Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University’s Medical Sciences Business Development & Partnering team reflect on 2018 and look forward to 2019

The Business Development & Partnering team standing together surrounded by festive Christmas decoration

2018 was a landmark year for the Divisional Business Development and Partnering Team. In addition to strengthening our research alliances with UCB, Novo Nordisk, Celgene, Pfizer and Bayer, we also saw some important strategic developments. We were delighted to welcome Novo Nordisk to Oxford in the summer, with the opening of the Novo Nordisk Oxford Research Centre based on the Old Road Campus which will strengthen our research partnership. The summer also saw the opening of the BioEscalator, a hub for new and developing life science innovations.

We were thrilled to learn that Innovate UK and industry are to invest more than £17.5 million in the University of Oxford to develop artificial intelligence (AI) healthcare applications. Funding will be provided through the Government’s Industrial Strategy Challenge Fund by as part of a £50 million investment to establish a network of digital pathology, imaging and AI centres, to drive innovation in the use of AI for improved diagnosis and delivery of precision treatments.

We have continued to deliver a range of events to engage our research community with industry, including the 2018 AIMday in Biomedical Imaging which was a huge success and we hope to repeat this in 2019 with a new AIMday in Advanced Therapies and Regenerative Medicine.

More recently, the Oxford MIT Healthcare Technologies of the Future Conference saw the University of Oxford and MIT come together to strengthen and share our industry networks and highlight some of our spin outs.

We are delighted to have developed, delivered and supported so many alliances, collaborations, opportunities and events in 2018 and look forward to a successful and fruitful 2019.

Find out more about the Business Development Team

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.